Alphamab Oncology (9966.HK)
Company Info
ISIN | KYG0330A1013 |
---|---|
Sector | Healthcare |
Industry | Biotechnology |
Highlights
Market Cap | HK$4.32B |
---|---|
Revenue (TTM) | HK$249.74M |
Gross Profit (TTM) | HK$142.99M |
EBITDA (TTM) | -HK$285.03M |
Year Range | HK$3.81 - HK$17.34 |
Target Price | HK$10.05 |
Share Price Chart
Loading data...
Compare to other instruments
Performance
Performance Chart
The chart shows the growth of an initial investment of HK$10,000 in Alphamab Oncology, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Alphamab Oncology had a return of -31.78% year-to-date (YTD) and -67.64% in the last 12 months.
Period | Return | Benchmark |
---|---|---|
Year-To-Date | -31.78% | 10.16% |
1 month | -13.05% | 3.47% |
6 months | -49.94% | 22.20% |
1 year | -67.64% | 30.45% |
5 years (annualized) | N/A | 13.16% |
10 years (annualized) | N/A | 10.89% |
Monthly Returns Heatmap
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024 | -40.51% | 27.09% | ||||||||||
2023 | -4.00% | -0.35% | 33.72% | -45.13% | 5.23% |
Risk-Adjusted Performance
Risk-Adjusted Performance Indicators
This table presents risk-adjusted performance metrics for Alphamab Oncology (9966.HK) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Sharpe ratio | Sortino ratio | Omega ratio | Calmar ratio | Ulcer Index | |
---|---|---|---|---|---|
Alphamab Oncology | -0.93 | ||||
S&P 500 | 2.79 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Alphamab Oncology. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Alphamab Oncology was 86.09%, occurring on Feb 5, 2024. The portfolio has not yet recovered.
The current Alphamab Oncology drawdown is 83.68%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-86.09% | Jul 15, 2021 | 632 | Feb 5, 2024 | — | — | — |
-56.75% | May 21, 2020 | 226 | Apr 20, 2021 | 23 | May 24, 2021 | 249 |
-30.77% | Feb 27, 2020 | 16 | Mar 19, 2020 | 37 | May 15, 2020 | 53 |
-22.29% | May 25, 2021 | 9 | Jun 4, 2021 | 13 | Jun 24, 2021 | 22 |
-13.51% | Dec 17, 2019 | 17 | Jan 13, 2020 | 18 | Feb 10, 2020 | 35 |
Volatility
Volatility Chart
The current Alphamab Oncology volatility is 14.65%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Income Statement
TTM | |
---|---|
Revenue | |
Total Revenue | 0.00 |
Cost Of Revenue | 0.00 |
Gross Profit | 0.00 |
Operating Expenses | |
Selling, General & Admin Expenses | 0.00 |
R&D Expenses | 0.00 |
Total Operating Expenses | 0.00 |
Income | |
Income Before Tax | 0.00 |
Operating Income | 0.00 |
EBIT | 0.00 |
Earnings From Continuing Operations | 0.00 |
Net Income | 0.00 |
Income Tax Expense | 0.00 |
Interest Expense | 0.00 |
Other Non-Operating Income (Expenses) | 0.00 |
Extraordinary Items | 0.00 |
Discontinued Operations | 0.00 |
Effect Of Accounting Charges | 0.00 |
Non Recurring | 0.00 |
Minority Interest | 0.00 |
Other Items | 0.00 |